Get Multiple Myeloma Drugs Market INFOGRAPHICS 2019: The Approval Of New Drugs To Drive The Multiple Myeloma Drugs Market

The global Multiple Myeloma Drugs Market was valued at US$ XX Mn in the year 2018 and is expected to reach US$ XX Mn by the year 2026, growing at a CAGR of 11.8%.

FREMONT, United States - May 22, 2019 /MarketersMedia/ —

Industrial Analysis of Multiple Myeloma Drugs Market
Multiple myeloma is a type of blood cancer that forms in plasma cells. Plasma cells are an important part of a person’s immune system, as they make antibodies that help fight infections.

Multiple myeloma is the second most common haematological cancer. In the year 2016, there were about 130,000 cases of multiple myeloma globally. In the same year, approximately 98,000 deaths were caused by multiple myeloma. The incidence of multiple myeloma is increasing across the globe.

Get Sample INFOGRAPHICS of Multiple Myeloma Drugs Market Report:
https://www.alltheresearch.com/sample-request/107

One of the major factors to drive the growth of the multiple myeloma drugs market is the approval of new drugs for the treatment of this type of cancer. For instance, in March 2019, the National Institute for Health and Care Excellence (NICE) approved Daratumumab in combination with bortezomib and dexamethasone, for the treatment of multiple myeloma. In 2016, the U.S. FDA approved the use of daratumumab in combination with dexamethasone and lenalidomide, or dexamethasone and bortezomib, for multiple myeloma patients who have received at least one prior therapy.
In Feb 2019, Sanofi, another leading pharmaceutical company, has declared the results of Phase III studies for its anti-CD38 therapy, isatuximab. The results revealed that the drug candidate helped in extending progression-free survival in patients with multiple myeloma.

However, most of the drugs used for the treatment of multiple myeloma are nearing patent-expiry. For instance, Celgene Corporation’s Revlimid is slated to lose its patent exclusivity at the end 2019. The looming threat of patent expiry of these drugs is expected to impede the growth of the multiple myeloma drugs market.

Top Company Profiles:
The major players operating in the multiple myeloma drugs market are Bristol-Myers Squibb, Celgene Corporation, Janssen Biotech, Inc., Novartis AG (Switzerland), Genzyme Corporation, Amgen, Inc., and Millennium Pharmaceuticals, amongst others.
Most of these companies are directing their efforts towards launching combination therapies for the treatment of multiple myeloma. Celgene is one of the leading players in the multiple myeloma drugs market. It has one drug in Phase III and five drugs is Phase II clinical trials for the treatment of relapsed/refractory multiple myeloma.

INFOGRAPICS Available for this Report in Special Discounted Price, Speak to Analyst and get more information
https://www.alltheresearch.com/speak-to-analyst/107

Recent News of Multiple Myeloma Drugs Market:
• In 2016, AbbVie and Bristol-Myers Squibb announced the EU approval of Empliciti™ (elotuzumab) for the treatment of adult multiple myeloma patients who have received at least one prior therapy. Empliciti™ (elotuzumab) has been approved for use in combination with dexamethasone and lenalidomide.
• In March 2018, Celgene Corporation completed the acquisition of Juno Therapeutics, Inc. This acquisition will position Celgene as a leading cellular immunotherapy company.
• In January 2019, Bristol-Myers Squibb has announced its plan to acquire Celgene Corporation for a whopping US$ 74 billion. The deal is expected to be completed by the third quarter of 2019.

Key questions answered:
• What is the value of the overall multiple myeloma drugs market and its segments?
• What is the value of the key segments and sub-segments in the multiple myeloma drugs market?
• Which are the attractive segments and geographies for investment?
• Who are the major players in the multiple myeloma drugs market and what are the key sustainable strategies of growth adopted by these players?
• What are the key unmet needs in major multiple myeloma drugs market?

View Complete Report with TOC, Tables and Figures:
https://www.alltheresearch.com/report/107/multiple-myeloma-drugs-market

Contact Info:
Name: Rohit B.
Email: Send Email
Organization: AllTheResearch
Address: 39180 LIBERTY STREET SUITE 110, FREMONT, CA 94538, USA
Phone: 8886916870
Website: https://www.alltheresearch.com

Source URL: https://marketersmedia.com/get-multiple-myeloma-drugs-market-infographics-2019-the-approval-of-new-drugs-to-drive-the-multiple-myeloma-drugs-market/516022

Source: MarketersMedia

Release ID: 516022

Latest News

US priest who gave out gifts in Philippines accused of abuse

Sep 15, 2019

TALUSTUSAN, Philippines — The American priest's voice echoed over the phone line, his sharp Midwestern accent softened over the decades by a gentle Filipino lilt. On the other end, recording the call, was a young man battered by shame but anxious to get the priest to describe exactly what had happened in this little island village. "I should have known better than trying to just have a life," the priest said in the November 2018 call. "Happy days are gone. It's all over." But, the young man later told the Associated Press, those days were happy only for the priest....

In Japan, a court case highlights paternity leave issues

Sep 15, 2019

TOKYO — He sits in an office of a major Japanese sportswear maker but reports to no one. He is assigned odd tasks like translating into English the manual on company rules like policies on vacations and daily hours, though he has minimal foreign language skills. He was sidelined, he says, as retribution for taking paternity leaves after each of his two sons was born. Now he's the plaintiff in one of the first lawsuits in Japan over "pata-hara," or paternity harassment, as it is known here. The first hearing is scheduled for this week. His case is unusual in...

China ban on some textbooks seen aimed at Uighur culture

Sep 15, 2019

BEIJING — For 15 years, Yalqun Rozi skillfully navigated state bureaucracies to publish textbooks that taught classic poems and folk tales to millions of his fellow minority Uighurs in China's far western region of Xinjiang. That all changed three years ago when the ruling Communist Party launched what it says is a campaign against ethnic separatism and religious extremism in Xinjiang. Suddenly even respected public figures like Rozi were being arrested, caught up in a crackdown that critics have said amounts to cultural genocide. An estimated 1 million Uighurs have since been detained in internment camps and prisons across the...

Hong Kong police and protesters clash, ending violence lull

Sep 15, 2019

HONG KONG — Hong Kong protesters threw bricks and gasoline bombs at police, who responded with tear gas, as chaotic scenes returned to the summer-long anti-government protests on Saturday for the first time in nearly two weeks. Hundreds of black-clad protesters armed with bamboo poles and baseball bats fought with police officers wielding batons on a main road following a march against "smart lampposts" that was sparked by surveillance fears. The chaotic scenes unfolded outside a police station and a nearby shopping mall as officers in riot gear faced off with protesters who set up makeshift street barricades. The violence...

Chinese pop stars publicly back Beijing on Hong Kong

Sep 15, 2019

HONG KONG — At least eight pop stars from mainland China and one each from Taiwan and Hong Kong are publicly stating their support for Beijing's one-China policy, eliciting a mixture of disappointment and understanding from fans. Many of the statements came after protesters opposed to Beijing's growing influence over semi-autonomous Hong Kong removed a Chinese flag and tossed it into Victoria Harbour earlier this month. Lay Zhang, Jackson Wang, Lai Kuan-lin and Victoria Song were among the K-pop singers who recently uploaded a Chinese flag and declared themselves as "one of 1.4 billion guardians of the Chinese flag" on...